Award details

Application of a commensal gut bacterium for the controlled delivery of heterologous proteins to the lower GI tract

Reference	BB/L004291/1
Principal Investigator / Supervisor	Professor Simon Carding
Co-Investigators / Co-Supervisors
Institution	University of East Anglia
Department	Norwich Medical School
Funding type	Research
Value (£)	831,445
Status	Completed
Type	Research Grant
Start date	02/12/2013
End date	01/06/2016
Duration	30 months

Abstract

unavailable

Summary

Oral administration is the preferred route for delivering therapeutic proteins to the gut. To be effective, significant obstacles including minimising loss of activity during transit and controlling the dose delivered must be overcome. Our technology is designed to overcome these obstacles and uses the human commensal gut bacterium, Bacteroides ovatus (Bo) to deliver therapeutic agents in the gut in response to the dietary plant based sugar, xylan. This drug delivery platform technology will be further developed using a characterised model Bo strain producing a potent anti-inflammatory agent that can effectively treat and prevent gut inflammation. Determining optimal dosing and delivery regimens and the impact of Bo and xylan dosing on resident gut bacteria and demonstrating functionality in the large bowel will achieve this. The final output will be a robustly characterised delivery technology with pre-clinical proof of safety and functionality for the delivery of therapeutic proteins

Committee	Not funded via Committee
Research Topics	Microbiology, Pharmaceuticals
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund Super (SuperFOF) [2012-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search